FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1781 December 13, 2001 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A small but growing number of patients with human immunodeficiency virus (HIV) infection undergo orthotopic liver transplantation for complications of intercurrent infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or both. HCV invariably reinfects liver allografts, typically causing a lobular hepatitis, and is reasonably well tolerated in the short term. If hepatitis B recurs after transplantation, it frequently causes devastating disease characterized by a rapidly progressive pathological process termed fibrosing cholestatic hepatitis, resulting in liver failure.¹ The postulated mechanism of this process is unimpeded viral replication mediated by immunosuppression in the transplant recipient. HIV has . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Verma, S. (2006). HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?. J Antimicrob Chemother 58: 496-501 [Abstract] [Full Text]  
• Roland, M. E., Lo, B., Braff, J., Stock, P. G. (2003). Key Clinical, Ethical, and Policy Issues in the Evaluation of the Safety and Effectiveness of Solid Organ Transplantation in HIV-Infected Patients. Arch Intern Med 163: 1773-1778 [Full Text]